Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.02+3.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ELDN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ELDN — earnings in line
Dated 2026-08-13
of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: FDA guidance is key for moving tegoprubart into Phase 3 trials. This could impact future funding and development.
Supportive ifThe FDA gave guidance on the Phase 3 trial design for tegoprubart in kidney transplants.
Worry ifNo FDA guidance received or delays in the Phase 3 trial design.
Why it matters: Starting new trials can show progress in drug development and open market chances.
Supportive ifThere is news about new studies for tegoprubart in liver and kidney transplants.
Worry ifNo new trials initiated or delays in starting planned studies.
Why it matters: A drop in cash reserves could signal funding challenges ahead. This impacts the company's ability to support ongoing trials.
Worry ifCash, cash equivalents, and short-term investments are more than $80 million.
Less concerning ifCash, cash equivalents, and short-term investments are less than $80 million.
Why it matters: High operating losses show problems with cost management. Investors will look for better results.
Worry ifQ2 operating losses reported at -$39 million or worse.
Less concerning ifOperating losses improve to -$30 million or less.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$179 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $702 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,812 loss on $10,000 · 68.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: High cash burn could threaten funding for ongoing trials and operations, impacting growth.
Worry ifCash burn stays below $20 million each quarter, helping operations into 2027.
Less concerning ifCash burn goes over $20 million each quarter, raising worries about funding.
Why it matters: Trends in net loss can show financial health and how well management controls costs.
Worry ifNet loss reported is lower than $39 million in the next earnings report.
Less concerning ifNet loss reported is higher than $39 million in the next earnings report.
Why it matters: New data may show how well tegoprubart works. This could affect investor trust.
Supportive ifLong-term data from Phase 1b and Phase 2 BESTOW studies show better graft function.
Worry ifData shows no better graft function or safety profile.
Why it matters: If the healthcare sector slows, it could impact Eledon's growth and operations.
Worry ifSector revenue growth has been below average for two months in a row.
Less concerning ifSector revenue growth remains above its median.
Why it matters: Starting this trial is a key step for Eledon. It shows progress in drug development and regulatory approval.
Supportive ifThe Phase 3 trial is initiated as planned in late 2026 with 600 patients.
Worry ifThe trial is delayed beyond late 2026 or fails to enroll the planned number of patients.
Why it matters: FDA feedback is crucial for moving forward with islet cell trials. It impacts future growth opportunities.
Supportive ifEledon gets good news from the FDA about tegoprubart for islet cell transplants.
Worry ifFDA news is bad or shows big problems for the islet cell program.
Why it matters: New data can strengthen the case for tegoprubart. Positive results can attract more interest and funding.
Supportive ifEledon shares new long-term data. It shows better kidney function and patient outcomes from the BESTOW trial.
Worry ifData shows no big changes when compared to tacrolimus. There are no positive or negative results.